Key result
Early revascularization and shortened DAPT reduce ischemic events and major bleeding in older MI patients.
Why the study?
Managing myocardial infarction in older adults (≥75–80 years) presents a complex clinical challenge due to age-related physiological changes, multimorbidity, renal impairment, biological frailty, atypical presentations, and the need to balance heightened ischemic and bleeding risks.
What are the optimal revascularization and antithrombotic management strategies for older adults (≥75–80 years) presenting with myocardial infarction?
What are the optimal revascularization and antithrombotic management strategies for older adults (≥75–80 years) presenting with myocardial infarction?
Managing myocardial infarction in older adults (≥75–80 years) requires tailoring invasive revascularization and shortened or de-escalated antithrombotic regimens based on frailty, renal function, and bleeding risk within a person-centered care pathway.
Answers are grounded in this paper and cite their sources.
Supports frailty-guided revascularization and shortened DAPT in older MI patients; leaves open dedicated trials in frail subgroups.
Managing myocardial infarction in older adults (≥75–80 years) presents a complex clinical challenge due to age-related physiological changes, multimorbidity, renal impairment, and biological frailty. Older patients frequently present with atypical clinical features without classic chest pain, displaying instead shortness of breath, sudden weakness, syncope, or delirium, which delays prompt diagnosis and risk stratification. Regarding revascularization strategies, primary percutaneous coronary intervention (PCI) remains the standard of care for ST-elevation myocardial infarction (STEMI). In non-ST-elevation myocardial infarction (NSTEMI), evidence from trials such as SENIOR-RITA, FIRE, and After Eighty indicates that an early invasive approach and complete physiology-guided revascularization significantly reduce recurrent ischemic events and urgent revascularizations in functionally active seniors. Conversely, in severely frail individuals with excessive comorbidities, conservative optimal medical therapy is preferred. Pharmacotherapy requires balancing heightened ischemic and bleeding risks. Due to high bleeding risk (HBR), shortening dual antiplatelet therapy (DAPT) duration (1–3 or ≤6 months) or adopting a uniform de-escalation strategy (e.g., transitioning to clopidogrel) significantly decreases major bleeding complications. For patients requiring oral anticoagulation, registry and clinical trial data (PERSEO, AUGUSTUS, RE-DUAL PCI) demonstrate that dual antithrombotic therapy combining a direct oral anticoagulant (DOAC) with a P2Y12 inhibitor is substantially safer than prolonged triple antithrombotic therapy (TAT). Concomitant gastroprotection with proton pump inhibitors (PPIs) and dosage adjustment of secondary prevention drugs according to renal function (eGFR) are essential. Ultimately, management must integrate comprehensive geriatric assessments and a multidisciplinary team approach to transition from a disease-centered model to a person-centered care pathway prioritized around quality of life.
No takes yet. Share an insight, caveat, or question.
Giorgi Nikolaishvili (2026) conducted a review in Myocardial infarction (STEMI and NSTEMI). Early invasive revascularization and tailored antithrombotic therapy (shortened DAPT of 1–3 or ≤6 months, or DOAC plus P2Y12 inhibitor) vs. Conservative optimal medical therapy or prolonged triple antithrombotic therapy was evaluated on Recurrent ischemic events, urgent revascularizations, and major bleeding complications. In older adults (≥75–80 years) with MI, early invasive revascularization in active seniors and shortened DAPT (1–3 or ≤6 months) or dual therapy reduce ischemic events and major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: